95 related articles for article (PubMed ID: 8355462)
1. Contributing factors to the inhibition of phagocytosis in hemodialyzed patients.
Vanholder R; Van Biesen W; Ringoir S
Kidney Int; 1993 Jul; 44(1):208-14. PubMed ID: 8355462
[TBL] [Abstract][Full Text] [Related]
2. Uraemic toxic retention solutes depress polymorphonuclear response to phagocytosis.
Vanholder R; De Smet R; Jacobs V; Van Landschoot N; Waterloos MA; Vogeleere P; Ringoir S
Nephrol Dial Transplant; 1994; 9(9):1271-8. PubMed ID: 7816288
[TBL] [Abstract][Full Text] [Related]
3. Depressed phagocytosis in hemodialyzed patients: in vivo and in vitro mechanisms.
Vanholder R; Dell'Aquila R; Jacobs V; Dhondt A; Veys N; Waterloss MA; Van Landschoot N; Van Biesen W; Ringoir S
Nephron; 1993; 63(4):409-15. PubMed ID: 8459876
[TBL] [Abstract][Full Text] [Related]
4. Correction of deficient phagocytosis during erythropoietin treatment in maintenance hemodialysis patients.
Veys N; Vanholder R; Ringoir S
Am J Kidney Dis; 1992 Apr; 19(4):358-63. PubMed ID: 1562025
[TBL] [Abstract][Full Text] [Related]
5. Antibiotics and energy delivery to the phagocytosis-associated respiratory burst in chronic hemodialysis patients: a comparison of cefodizime and cotrimoxazole.
Vanholder R; Dagrosa EE; Van Landschoot N; Waterloos MA; Ringoir SM
Nephron; 1993; 63(1):65-72. PubMed ID: 8446254
[TBL] [Abstract][Full Text] [Related]
6. Dialyzer membrane type and reuse practice influence polymorphonuclear leukocyte function in hemodialysis patients.
Rao M; Guo D; Jaber BL; Sundaram S; Cendoroglo M; King AJ; Pereira BJ; Balakrishnan VS;
Kidney Int; 2004 Feb; 65(2):682-91. PubMed ID: 14717942
[TBL] [Abstract][Full Text] [Related]
7. Polymorphonuclear cell function and infection in dialysis.
Vanholder R; Ringoir S
Kidney Int Suppl; 1992 Oct; 38():S91-5. PubMed ID: 1405386
[TBL] [Abstract][Full Text] [Related]
8. Impaired phagocytosis in chronic renal failure is mediated by secondary hyperparathyroidism.
Chervu I; Kiersztejn M; Alexiewicz JM; Fadda GZ; Smogorzewski M; Massry SG
Kidney Int; 1992 Jun; 41(6):1501-5. PubMed ID: 1501406
[TBL] [Abstract][Full Text] [Related]
9. Relationship between phagocyte metabolic function and years of maintenance dialysis.
Vanholder R; Van Biesen W; Van Lanschoot N; Waterloos MA; Ringoir S
ASAIO Trans; 1990; 36(3):M469-72. PubMed ID: 2123637
[TBL] [Abstract][Full Text] [Related]
10. Impaired phagocytosis in dialysis patients: studies on mechanisms.
Alexiewicz JM; Smogorzewski M; Fadda GZ; Massry SG
Am J Nephrol; 1991; 11(2):102-11. PubMed ID: 1951470
[TBL] [Abstract][Full Text] [Related]
11. Epoetin requirement does not depend on dialysis dose when Kt/N > 1.33 in patients on regular dialysis treatment with cellulosic membranes and adequate iron stores.
Movilli E; Cancarini GC; Vizzardi V; Camerini C; Brunori G; Cassamali S; Maiorca R
J Nephrol; 2003; 16(4):546-51. PubMed ID: 14696757
[TBL] [Abstract][Full Text] [Related]
12. Effects of uraemia and dialysis modality on polymorphonuclear cell apoptosis and function.
Sardenberg C; Suassuna P; Andreoli MC; Watanabe R; Dalboni MA; Manfredi SR; dos Santos OP; Kallas EG; Draibe SA; Cendoroglo M
Nephrol Dial Transplant; 2006 Jan; 21(1):160-5. PubMed ID: 16155068
[TBL] [Abstract][Full Text] [Related]
13. Immune dysfunction in uremia.
Cohen G; Haag-Weber M; Hörl WH
Kidney Int Suppl; 1997 Nov; 62():S79-82. PubMed ID: 9350688
[TBL] [Abstract][Full Text] [Related]
14. Intradialytic changes of serum magnesium and their relation to hypotensive episodes in hemodialysis patients on different dialysates.
Elsharkawy MM; Youssef AM; Zayoon MY
Hemodial Int; 2006 Oct; 10 Suppl 2():S16-23. PubMed ID: 17022745
[TBL] [Abstract][Full Text] [Related]
15. Effect of leptin on polymorphonuclear leucocyte functions in healthy subjects and haemodialysis patients.
Cohen G; Raupachova J; Ilic D; Werzowa J; Hörl WH
Nephrol Dial Transplant; 2011 Jul; 26(7):2271-81. PubMed ID: 21216885
[TBL] [Abstract][Full Text] [Related]
16. Dialysis adequacy and nutritional status of hemodialysis patients.
Teixeira Nunes F; de Campos G; Xavier de Paula SM; Merhi VA; Portero-McLellan KC; da Motta DG; de Oliveira MR
Hemodial Int; 2008 Jan; 12(1):45-51. PubMed ID: 18271840
[TBL] [Abstract][Full Text] [Related]
17. Risk factors and risk for mortality of mild hypoparathyroidism in hemodialysis patients.
Guh JY; Chen HC; Chuang HY; Huang SC; Chien LC; Lai YH
Am J Kidney Dis; 2002 Jun; 39(6):1245-54. PubMed ID: 12046038
[TBL] [Abstract][Full Text] [Related]
18. Phagocytosis in uremic and hemodialysis patients: a prospective and cross sectional study.
Vanholder R; Ringoir S; Dhondt A; Hakim R
Kidney Int; 1991 Feb; 39(2):320-7. PubMed ID: 2002645
[TBL] [Abstract][Full Text] [Related]
19. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
20. Primed peripheral polymorphonuclear leukocyte: a culprit underlying chronic low-grade inflammation and systemic oxidative stress in chronic kidney disease.
Sela S; Shurtz-Swirski R; Cohen-Mazor M; Mazor R; Chezar J; Shapiro G; Hassan K; Shkolnik G; Geron R; Kristal B
J Am Soc Nephrol; 2005 Aug; 16(8):2431-8. PubMed ID: 15987755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
